Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM.


Journal

Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435

Informations de publication

Date de publication:
09 2019
Historique:
received: 16 03 2018
accepted: 15 01 2019
pubmed: 19 1 2019
medline: 29 7 2020
entrez: 19 1 2019
Statut: ppublish

Résumé

New drugs are needed for the treatment of relapsed acute lymphoblastic leukemia and preclinical evaluation of the MEK inhibitor, selumetinib, has shown that this drug has excellent activity in those leukemias with RAS pathway mutations. The proapoptotic protein, BIM is pivotal in the induction of cell death by both selumetinib and glucocorticoids, suggesting the potential for synergy. Thus, combination indices for dexamethasone and selumetinib were determined in RAS pathway-mutated acute lymphoblastic leukemia primagraft cells

Identifiants

pubmed: 30655370
pii: haematol.2017.185975
doi: 10.3324/haematol.2017.185975
pmc: PMC6717586
doi:

Substances chimiques

AZD 6244 0
BCL2L11 protein, human 0
Bcl-2-Like Protein 11 0
Benzimidazoles 0
Glucocorticoids 0
Dexamethasone 7S5I7G3JQL
ras Proteins EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1804-1811

Subventions

Organisme : Blood Cancer UK
ID : 11007
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 12788
Pays : United Kingdom
Organisme : Chief Scientist Office
ID : ETM/374
Pays : United Kingdom

Informations de copyright

Copyright© 2019 Ferrata Storti Foundation.

Références

Blood. 2004 Jul 15;104(2):307-13
pubmed: 14982869
Oncogene. 2004 Jul 8;23(31):5301-15
pubmed: 15241487
Cell Death Differ. 2005 Aug;12(8):1008-14
pubmed: 15947788
FEBS Lett. 2006 Jun 12;580(14):3539-44
pubmed: 16730715
Int J Hematol. 1991 Jun;54(3):219-30
pubmed: 1747457
Mol Cancer Ther. 2007 Aug;6(8):2209-19
pubmed: 17699718
J Clin Oncol. 2007 Dec 20;25(36):5800-7
pubmed: 18089878
J Clin Oncol. 2008 Apr 20;26(12):1932-9
pubmed: 18421047
Cancer Res. 2008 Aug 15;68(16):6803-9
pubmed: 18701506
Cell Death Differ. 2009 Mar;16(3):368-77
pubmed: 18846109
Nat Med. 2008 Dec;14(12):1351-6
pubmed: 19029981
Leukemia. 2009 Oct;23(10):1744-54
pubmed: 19404317
Leukemia. 2010 Jan;24(1):232-5
pubmed: 19776760
Leukemia. 2010 Feb;24(2):450-9
pubmed: 20016529
Invest New Drugs. 2011 Oct;29(5):1021-8
pubmed: 20127139
Blood. 2010 Oct 21;116(16):3013-22
pubmed: 20647567
PLoS One. 2010 Sep 27;5(9):e13026
pubmed: 20885957
Lancet. 2010 Dec 11;376(9757):2009-17
pubmed: 21131038
Immunol Res. 2011 Apr;49(1-3):248-68
pubmed: 21170740
Nature. 2011 Mar 10;471(7337):235-9
pubmed: 21390130
J Clin Oncol. 2011 Aug 10;29(23):3185-93
pubmed: 21747090
Nat Rev Cancer. 2011 Oct 13;11(11):761-74
pubmed: 21993244
Genes Chromosomes Cancer. 2012 Mar;51(3):250-6
pubmed: 22072526
Nat Rev Mol Cell Biol. 2011 Dec 22;13(1):39-51
pubmed: 22189424
Br J Cancer. 2012 Apr 10;106(8):1386-94
pubmed: 22415236
Blood. 2012 Oct 25;120(17):3397-406
pubmed: 22898602
Clin Cancer Res. 2013 Jan 1;19(1):118-27
pubmed: 23091117
Lancet Oncol. 2013 Jan;14(1):38-47
pubmed: 23200175
Cancer Cell. 2013 Jan 14;23(1):121-8
pubmed: 23245996
Lancet Oncol. 2013 Mar;14(3):199-209
pubmed: 23395119
J Clin Oncol. 2013 Dec 1;31(34):4333-42
pubmed: 24166518
Lancet Oncol. 2014 Jul;15(8):809-18
pubmed: 24924991
Front Oncol. 2014 Jun 24;4:160
pubmed: 25009801
Blood. 2014 Nov 27;124(23):3420-30
pubmed: 25253770
Ther Adv Med Oncol. 2015 Mar;7(2):122-36
pubmed: 25755684
Nat Commun. 2015 Mar 19;6:6604
pubmed: 25790293
Blood. 2015 Nov 5;126(19):2202-12
pubmed: 26324703
PLoS One. 2016 May 19;11(5):e0155893
pubmed: 27196001
N Engl J Med. 2016 Dec 29;375(26):2550-2560
pubmed: 28029918
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
Blood. 1995 Nov 15;86(10):3861-8
pubmed: 7579354

Auteurs

Elizabeth C Matheson (EC)

Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne.

Huw Thomas (H)

Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne.

Marian Case (M)

Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne.

Helen Blair (H)

Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne.

Rosanna K Jackson (RK)

Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne.

Dino Masic (D)

Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne.

Gareth Veal (G)

Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne.

Chris Halsey (C)

Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow.

David R Newell (DR)

Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne.

Josef Vormoor (J)

Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne.
Great North Children's Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

Julie A E Irving (JAE)

Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne j.a.e.irving@ncl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH